$PNST
Pinstripes Holdings, Inc.

2023 Q2 Form 10-Q Financial Statement

#000110465923093176 Filed on August 18, 2023

View on sec.gov

Income Statement

Concept 2023 Q2
Revenue $4.259K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $813.2K
YoY Change 291.26%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $3.208M
YoY Change 1158.19%
Operating Profit -$3.208M
YoY Change 1158.19%
Interest Expense $1.178M
YoY Change 200.45%
% of Operating Profit
Other Income/Expense, Net -$3.137M
YoY Change -273.0%
Pretax Income -$6.345M
YoY Change -507.12%
Income Tax $236.9K
% Of Pretax Income
Net Earnings -$6.582M
YoY Change -553.89%
Net Earnings / Revenue -154549.59%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.41
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $358.6K
YoY Change -49.11%
Cash & Equivalents $358.6K
Short-Term Investments
Other Short-Term Assets $191.6K
YoY Change -35.12%
Inventory $802.0K
Prepaid Expenses $191.6K
Receivables $1.310M
Other Receivables
Total Short-Term Assets $550.1K
YoY Change -44.97%
LONG-TERM ASSETS
Property, Plant & Equipment $62.84M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $42.19M
YoY Change -82.91%
Total Long-Term Assets $42.19M
YoY Change -82.91%
TOTAL ASSETS
Total Short-Term Assets $550.1K
Total Long-Term Assets $42.19M
Total Assets $42.74M
YoY Change -82.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $252.8K
YoY Change 103.18%
Accrued Expenses $2.547M
YoY Change 1146.43%
Deferred Revenue
YoY Change
Short-Term Debt $400.0K
YoY Change
Long-Term Debt Due $1.044M
YoY Change
Total Short-Term Liabilities $5.575M
YoY Change 1595.7%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $8.899M
YoY Change -30.5%
Total Long-Term Liabilities $8.899M
YoY Change -30.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.575M
Total Long-Term Liabilities $8.899M
Total Liabilities $14.47M
YoY Change 10.21%
SHAREHOLDERS EQUITY
Retained Earnings -$13.92M
YoY Change 16.07%
Common Stock $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$13.92M
YoY Change
Total Liabilities & Shareholders Equity $42.74M
YoY Change -82.76%

Cashflow Statement

Concept 2023 Q2
OPERATING ACTIVITIES
Net Income -$6.582M
YoY Change -553.89%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.945M
YoY Change 427.52%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $210.0M
YoY Change
Cash From Investing Activities $210.0M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -209.6M
YoY Change -419363.64%
NET CHANGE
Cash From Operating Activities -1.945M
Cash From Investing Activities 210.0M
Cash From Financing Activities -209.6M
Net Change In Cash -1.545M
YoY Change 384.77%
FREE CASH FLOW
Cash From Operating Activities -$1.945M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001852633
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
236909
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41236
dei Entity Registrant Name
EntityRegistrantName
BANYAN ACQUISITION CORP.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-2556699
dei Entity Address Address Line1
EntityAddressAddressLine1
400 Skokie Blvd
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 820
dei Entity Address City Or Town
EntityAddressCityOrTown
Northbrook
dei Entity Address State Or Province
EntityAddressStateOrProvince
IL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
60062
dei City Area Code
CityAreaCode
847
dei Local Phone Number
LocalPhoneNumber
757-3812
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
true
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
358560
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
510893
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
191572
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
256157
CY2023Q2 us-gaap Assets Current
AssetsCurrent
550132
CY2022Q4 us-gaap Assets Current
AssetsCurrent
767050
CY2023Q2 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
42190562
CY2022Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
250326857
CY2022Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
12764
CY2023Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
42190562
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
250339621
CY2023Q2 us-gaap Assets
Assets
42740694
CY2022Q4 us-gaap Assets
Assets
251106671
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2547000
CY2023Q2 byn Income Tax Payable Current
IncomeTaxPayableCurrent
255326
CY2022Q4 byn Income Tax Payable Current
IncomeTaxPayableCurrent
783546
CY2023Q2 byn Accrued Franchise Tax Expense Current
AccruedFranchiseTaxExpenseCurrent
19178
CY2022Q4 byn Accrued Franchise Tax Expense Current
AccruedFranchiseTaxExpenseCurrent
193490
CY2023Q2 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
2100318
CY2023Q2 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
400000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
252767
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
244891
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
5574589
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1221927
CY2023Q2 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
5276500
CY2022Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
599875
CY2023Q2 byn Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
3622500
CY2022Q4 byn Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
9660000
CY2023Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
8899000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
10259875
CY2023Q2 us-gaap Liabilities
Liabilities
14473589
CY2022Q4 us-gaap Liabilities
Liabilities
11481802
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13924182
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-10702713
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-13923457
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-10701988
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42740694
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
251106671
byn Warrant Issuance Expense
WarrantIssuanceExpense
500307
CY2023Q2 byn Exchange Listing Fees
ExchangeListingFees
21249
CY2022Q2 byn Exchange Listing Fees
ExchangeListingFees
20178
byn Exchange Listing Fees
ExchangeListingFees
42269
byn Exchange Listing Fees
ExchangeListingFees
120365
CY2023Q2 us-gaap Legal Fees
LegalFees
2373475
CY2022Q2 us-gaap Legal Fees
LegalFees
26945
us-gaap Legal Fees
LegalFees
2513475
us-gaap Legal Fees
LegalFees
121945
CY2023Q2 byn General And Administrative Other Expenses
GeneralAndAdministrativeOtherExpenses
813203
CY2022Q2 byn General And Administrative Other Expenses
GeneralAndAdministrativeOtherExpenses
207840
byn General And Administrative Other Expenses
GeneralAndAdministrativeOtherExpenses
1030413
byn General And Administrative Other Expenses
GeneralAndAdministrativeOtherExpenses
435861
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
3207927
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
254963
us-gaap Operating Expenses
OperatingExpenses
3586157
us-gaap Operating Expenses
OperatingExpenses
1178478
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3207927
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-254963
us-gaap Operating Income Loss
OperatingIncomeLoss
-3586157
us-gaap Operating Income Loss
OperatingIncomeLoss
-1178478
CY2023Q2 byn Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
-4224105
CY2022Q2 byn Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
1459707
byn Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
-4676625
byn Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
11760463
CY2023Q2 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
4259
us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
15090
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1173738
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
392079
us-gaap Investment Income Interest
InvestmentIncomeInterest
3891253
us-gaap Investment Income Interest
InvestmentIncomeInterest
457476
CY2023Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-91323
CY2022Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-38227
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-107187
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-38227
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3137431
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1813559
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-877469
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12179712
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6345358
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1558596
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4463626
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
11001234
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
236909
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
108421
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
799505
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
108421
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6582267
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
1450175
us-gaap Net Income Loss
NetIncomeLoss
-5263131
us-gaap Net Income Loss
NetIncomeLoss
10892813
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-10701988
CY2023Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
813105
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
1319136
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-10195957
CY2023Q2 byn Sponsor Capital Contribution For Non Redemption Agreements
SponsorCapitalContributionForNonRedemptionAgreements
844916
CY2023Q2 byn Non Redemption Agreements
NonRedemptionAgreements
844916
CY2023Q2 byn Decrease In Equity Excise Tax
DecreaseInEquityExciseTax
-2100318
CY2023Q2 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1082415
CY2023Q2 byn Increase In Equity Reduction Of Deferred Underwriter Fee Payable
IncreaseInEquityReductionOfDeferredUnderwriterFeePayable
6037500
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6582267
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-13923457
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
2748
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
4504363
CY2022Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
65397
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
9442637
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-13091872
CY2022Q2 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
353852
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
1450175
byn Condition For Future Business Combination Number Of Businesses Minimum
ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum
1
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-11995549
us-gaap Net Income Loss
NetIncomeLoss
-5263131
us-gaap Net Income Loss
NetIncomeLoss
10892813
us-gaap Investment Income Interest
InvestmentIncomeInterest
3891253
us-gaap Investment Income Interest
InvestmentIncomeInterest
457476
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-107187
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-38227
byn Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
-4676625
byn Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
11760463
byn Warrant Issuance Expense
WarrantIssuanceExpense
500307
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-77349
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
432442
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2547000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4703
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-528220
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
108421
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7876
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
124405
byn Increase Decrease In Accrued Offering Costs
IncreaseDecreaseInAccruedOfferingCosts
-364557
byn Increase Decrease In Franchise Tax Payable
IncreaseDecreaseInFranchiseTaxPayable
-174312
byn Increase Decrease In Franchise Tax Payable
IncreaseDecreaseInFranchiseTaxPayable
87736
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2440879
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1267732
byn Payments For Investment Of Cash In Trust Account
PaymentsForInvestmentOfCashInTrustAccount
246330000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
210031815
byn Withdrawal From Trust Account For Taxes
WithdrawalFromTrustAccountForTaxes
1888546
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
211920361
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-246330000
byn Net Proceeds From Initial Public Offering
NetProceedsFromInitialPublicOffering
236670000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
11910000
byn Payment For Redemption Of Temporary Equity
PaymentForRedemptionOfTemporaryEquity
210031815
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
289425
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
400000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
42392
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-209631815
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
248248183
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-152333
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
650451
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
510893
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54057
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
358560
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
704508
byn Initial Classification Of Common Stock Subject To Possible Redemption
InitialClassificationOfCommonStockSubjectToPossibleRedemption
219353777
byn Remeasurement Of Class Common Stock Subject To Possible Redemption
RemeasurementOfClassCommonStockSubjectToPossibleRedemption
1895520
byn Remeasurement Of Class Common Stock Subject To Possible Redemption
RemeasurementOfClassCommonStockSubjectToPossibleRedemption
27395472
byn Deferred Underwriting Fee Payable
DeferredUnderwritingFeePayable
9660000
byn Initial Fair Value Of Warrant Liabilities
InitialFairValueOfWarrantLiabilities
14904213
byn Reduction Of Deferred Underwriter Fee Payable
ReductionOfDeferredUnderwriterFeePayable
-6037500
byn Excise Tax Liability Non Cash Investing And Financing Activities
ExciseTaxLiabilityNonCashInvestingAndFinancingActivities
2100318
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Banyan Acquisition Corporation (the “Company”) is a blank check company incorporated in Delaware on March 10, 2021. The Company was incorporated for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (“Initial Business Combination”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, the Company had not commenced any operations. All activity for the period from March 10, 2021 (inception) through June 30, 2023, relates to the Company’s formation, the initial public offering (“Initial Public Offering”), which is described below, and pursuit of an Initial Business Combination. The Company will not generate any operating revenues until after the completion of an Initial Business Combination, at the earliest. The Company will generate non-operating income in the form of unrealized gains and interest income from the proceeds derived from the Initial Public Offering. The Company has selected December 31 as its fiscal year end. Panther Merger Sub Inc. is a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”) with no activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The registration statement for the Company’s Initial Public Offering was declared effective on January 19, 2022. On January 24, 2022, the Company consummated its Initial Public Offering of 24,150,000 Units at $10.00 per Unit, generating gross proceeds of $241,500,000, which is discussed in Note 3. Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 11,910,000 Private Placement Warrants (the “Private Placement Warrants”) to Banyan Acquisition Sponsor LLC (the “Sponsor”), BTIG, LLC and I-Bankers Securities, Inc., at an exercise price of $1.00 per Private Placement Warrant, for an aggregate of $11,910,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Following the closing of the Initial Public Offering on January 24, 2022, $246,330,000 ($10.20 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (“Trust Account”), located in the United States which will be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 180 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of an Initial Business Combination and (ii) the redemption of any Public Shares properly submitted in connection with a stockholder vote to amend the Company’s amended and restated certificate of incorporation, and (iii) the redemption of the Company’s Public Shares if the Company is unable to complete the initial Business Combination by December 24, 2023 (the “Combination Period”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At a reconvened special meeting of stockholders held on April 21, 2023 (the “Special Meeting”), the Company’s stockholders approved, and the Company subsequently adopted, (x) an amendment to the Company’s amended and restated certificate of incorporation (the “Charter Amendment”) which provided that (i) the Company shall have the option to extend the period by which it must complete an Initial Business Combination by eight months, from April 24, 2023 to December 24, 2023 (the “Extension Option”) and (ii) that each of the holders of shares of the Company’s Class B common stock shall have the right at any time to convert any and all of their shares of the Company’s Class B common stock to shares of the Company’s Class A common stock on a one-for-one basis prior to the closing of an Initial Business Combination, at the election of such holder and (y) an amendment to the Investment Management Trust Agreement (the “Trust Amendment”), which provided that the Company shall have the right to extend the period by which it must complete an Initial Business Combination by eight months, from April 24, 2023 to December 24, 2023, without having to make any payment to the trust account established in connection with the Company’s initial public offering. Additionally, in connection with the Special Meeting, the Company and the Sponsor entered into certain non-redemption agreements with certain unaffiliated third parties, pursuant to which the Sponsor agreed to transfer an aggregate of 1,018,750 shares of Class B common stock to such third parties immediately following consummation of an Initial Business Combination if such third parties continued to hold certain amounts of Class A common stock through the closing of the Special Meeting and assuming the Charter Amendment and the Trust Amendment were adopted. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the stockholders’ vote at the Special Meeting, holders of 20,151,313 shares of Class A common stock exercised their right to redeem their shares for cash at an approximate price of $10.42 per share, which resulted in an aggregate payment to such redeeming holders of $210,031,815. As of June 30, 2023 (and inclusive of the payment referenced in the preceding sentence), the trust account balance was $42,190,562.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Charter Amendment and the Trust Amendment received the requisite votes at the Special Meeting and were subsequently adopted by the Company. On April 21, 2023, the Company filed the Charter Amendment with the Secretary of State for the State of Delaware. On April 21, 2023, the Company exercised the Extension Option, extending the time allotted to complete an Initial Business Combination by eight months, from April 24, 2023 to December 24, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On April 21, 2023, pursuant to the terms of the Charter Amendment, the Sponsor converted 2,000,000 shares of Class B common stock held by it on a one-for-one basis into shares of Class A common stock with immediate effect. Following such conversion and taking into account the redemptions described above, there are 5,998,687 shares of Class A common stock issued and <span style="-sec-ix-hidden:Hidden_qSveRSFBjUWn0Yb_GocCtQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> and 5,245,000 shares of Class B common stock issued and <span style="-sec-ix-hidden:Hidden_iRQyaDpxcke0b3w_GTkqRA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> as of the date hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on the world economy are not determinable as of the date of these financial statements and the specific impact on the Company’s financial condition, results of operations, and cash flows is also not determinable as of the date of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 16, 2022, the Inflation Reduction Act of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases (including redemptions) of stock by publicly traded domestic (i.e., U.S.) corporations and certain domestic subsidiaries of publicly traded foreign corporations. The excise tax is imposed on the repurchasing corporation itself, not its stockholders from whom shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury has been given authority to provide regulations and other guidance to carry out, and prevent the abuse or avoidance of the excise tax. The IR Act applies only to repurchases that occur after December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On April 21, 2023, the Company’s stockholders redeemed 20,151,313 Class A shares for a total of $210,031,815 in connection with the stockholder vote to approve the Company’s extension. The Company evaluated the classification and accounting of the stock redemption under ASC 450, “Contingencies”. ASC 450 states that when a loss contingency exists the likelihood that the future events will confirm the loss or impairment of an asset or the incurrence of a liability can range from probable to remote. A contingent liability must be reviewed at each reporting period to determine appropriate treatment. The Company evaluated the current status and probability of completing an Initial Business Combination as of June 30, 2023 and determined that a contingent liability should be calculated and recorded. As of June 30, 2023, the Company recorded $2,100,318 of excise tax liability calculated as 1% of shares redeemed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The financial statements do not include any adjustments that might result from the outcome of these uncertainties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity, Capital Resources and Going Concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, the Company had $358,560 in operating cash and a working capital deficit of $5,024,457.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s liquidity needs up to June 30, 2023, had been satisfied through a payment from the Sponsor of $25,000 for Class B common stock, par value $0.0001 per share (“Class B common stock” and shares thereof, “Founder Shares”), the Initial Public Offering and the issuance of the Private Placement Warrants. Additionally, the Company drew on unsecured promissory notes to pay certain offering costs (see Note 5).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has incurred and expects to continue to incur significant costs in pursuit of its financing and acquisition plans. The Company lacks the financial resources it needs to sustain operations for a reasonable period of time, which is considered to be one year from the issuance date of the financial statements. Although no formal agreement exists, the Sponsor has agreed to extend Working </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Capital Loans as needed (defined in Note 5 below). Accordingly, the Company may not be able to obtain additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction and reducing overhead expenses. The Company cannot provide any assurance that (i) new financing will be available to it on commercially acceptable terms, if at all, or (ii) its plans to consummate an Initial Business Combination will be successful. In addition, management is currently evaluating the impact of the Russia/Ukraine war and its effect on the Company’s financial position, results of its operations and/or search for a target company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern through the end of the Combination Period on December 24, 2023. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>
CY2023Q2 byn Business Combination Extension Option
BusinessCombinationExtensionOption
P8M
CY2023Q2 byn Business Combination Extension Option
BusinessCombinationExtensionOption
P8M
CY2023Q2 byn Payments From Trust Account To Redeem Shares
PaymentsFromTrustAccountToRedeemShares
42190562
CY2023Q2 byn Business Combination Extension Option
BusinessCombinationExtensionOption
P8M
CY2023Q2 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
2100318
CY2023Q2 byn Percentage Of Excise Tax Liability On Shares Redeemed
PercentageOfExciseTaxLiabilityOnSharesRedeemed
0.01
CY2023Q2 us-gaap Cash
Cash
358560
CY2023Q2 byn Working Capital
WorkingCapital
5024457
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p>
CY2023Q2 us-gaap Cash
Cash
358560
CY2022Q4 us-gaap Cash
Cash
510893
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed federally insured limits. Exposure to cash and cash equivalents credit risk is reduced by placing such deposits with major financial institutions and monitoring their credit ratings. At June 30, 2023, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p>
CY2023Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
30821
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
23985000
byn Warrants And Rights Outstanding Exercisable Term From Closing Of Public Offering
WarrantsAndRightsOutstandingExercisableTermFromClosingOfPublicOffering
P12M
byn Warrants And Rights Outstanding Exercisable Term From Closing Of Business Combination
WarrantsAndRightsOutstandingExercisableTermFromClosingOfBusinessCombination
P30D
byn Threshold Period For Filling Registration Statement After Business Combination
ThresholdPeriodForFillingRegistrationStatementAfterBusinessCombination
P60D
byn Threshold Period For Filling Registration Statement Within Number Of Days Of Business Combination
ThresholdPeriodForFillingRegistrationStatementWithinNumberOfDaysOfBusinessCombination
P60D
byn Threshold Issue Price For Capital Raising Purposes In Connection With Closing Of Business Combination
ThresholdIssuePriceForCapitalRaisingPurposesInConnectionWithClosingOfBusinessCombination
9.20
CY2023Q2 byn Percentage Of Gross Proceeds On Total Equity Proceeds
PercentageOfGrossProceedsOnTotalEquityProceeds
0.60
byn Threshold Trading Days For Calculating Volume Weighted Average Trading Price
ThresholdTradingDaysForCalculatingVolumeWeightedAverageTradingPrice
P20D
byn Threshold Issue Price For Capital Raising Purposes In Connection With Closing Of Business Combination
ThresholdIssuePriceForCapitalRaisingPurposesInConnectionWithClosingOfBusinessCombination
9.20
CY2023Q2 byn Class Of Warrant Or Right Adjustment Of Exercise Price Of Warrants Or Rights Percent Based On Market Value
ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValue
1.15
CY2023Q2 byn Class Of Warrant Or Right Adjustment Of Redemption Price Of Warrants Or Rights Percent Based On Market Value
ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValue
1.80
byn Threshold Period For Not To Transfer Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination
ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination
P30D
CY2023Q2 byn Maximum Number Of Demands For Registration Of Securities
MaximumNumberOfDemandsForRegistrationOfSecurities
3
byn Underwriting Cash Discount Per Unit
UnderwritingCashDiscountPerUnit
0.20
byn Aggregate Underwriter Cash Discount
AggregateUnderwriterCashDiscount
4830000
CY2023Q2 byn Deferred Fee Per Unit
DeferredFeePerUnit
0.40
byn Aggregate Deferred Underwriting Fee Payable
AggregateDeferredUnderwritingFeePayable
9660000
CY2023Q2 byn Compensation From Deferred Underwriting Commission Plus Capital Markets Advisory Fee
CompensationFromDeferredUnderwritingCommissionPlusCapitalMarketsAdvisoryFee
3622500
CY2023Q2 byn Compensation From Deferred Underwriting Commission Plus Capital Markets Advisory Fee
CompensationFromDeferredUnderwritingCommissionPlusCapitalMarketsAdvisoryFee
3622500
CY2023Q2 byn Compensation From Deferred Underwriting Commission Plus Capital Markets Advisory Fee
CompensationFromDeferredUnderwritingCommissionPlusCapitalMarketsAdvisoryFee
3622500
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
799505
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
108421
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
108421
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0506
CY2022Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0696
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.2854
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0099
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21

Files In Submission

Name View Source Status
0001104659-23-093176-index-headers.html Edgar Link pending
0001104659-23-093176-index.html Edgar Link pending
0001104659-23-093176.txt Edgar Link pending
0001104659-23-093176-xbrl.zip Edgar Link pending
byn-20230630.xsd Edgar Link pending
byn-20230630x10q.htm Edgar Link pending
byn-20230630xex31d1.htm Edgar Link pending
byn-20230630xex31d2.htm Edgar Link pending
byn-20230630xex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
byn-20230630_cal.xml Edgar Link unprocessable
byn-20230630_def.xml Edgar Link unprocessable
byn-20230630x10q_htm.xml Edgar Link completed
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
byn-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
byn-20230630_lab.xml Edgar Link unprocessable